Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction

NCT04339712 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

102

Enrollment

OTHER

Sponsor class

Conditions

COVID-19
Virus Diseases
Macrophage Activation Syndrome
Corona Virus Infection

Interventions

DRUG: Anakinra
DRUG: Tocilizumab

Sponsor

Hellenic Institute for the Study of Sepsis